Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 03-29-2004, 07:08 AM   #1
Posts: n/a
NeoPharm Inc. (Nasdaq/NM:NEOL) announced today that pre-clinical data for a new formulation of LErafAON (Liposome entrapped c-raf antisense oligonucleotide) was presented via poster presentation on Sunday March 28th at the 2004 American Association for Cancer Research (AACR) in Orlando Florida. Copies of the two abstracts #637 and #638 are available on the NeoPharm website http://www.neophrm.com.

research posters for a formulation of a ready to use liposome entrapped raf antisense oligonucleotide (LErafAON) described anticancer effects of LErafAON against several mouse tumor models including human breast ovarian and prostate cancer in comparison - and in combination with - Taxol(R) and Taxotere(R).

Abstract #638 unveiled at the AACR meeting on Sunday March 28th provided evidence that in both human breast and ovarian tumor models LErafAON treatment inhibited tumor growth by 59% and 45% respectively whereas Taxol(R) inhibited ovarian tumor model by 41% and the combination of LErafAON and Taxol(R) inhibited ovarian tumor growth by 90%. These results suggest that LErafAON appears to act as a chemotherapeutic sensitizer and may prove useful to enhance the inhibitory effect of Taxol(R) in ovarian cancer growth.

  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 03:15 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter